PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1461171
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1461171
Global Anti-Inflammatory Biologics Market is valued approximately at USD 93.13 billion in 2022 and is anticipated to grow with a growth rate of more than 5.9% over the forecast period 2023-2030. Anti-inflammatory biologics are advanced medications designed to target and reduce inflammation in the body, primarily used for treating conditions such as psoriasis, ulcerative colitis, rheumatoid arthritis and inflammatory bowel diseases has spurred demand for biologics. They work by interfering with specific molecules or pathways in the immune system, helping alleviate symptoms and prevent tissue damage. These biologics have transformed the treatment landscape for inflammatory conditions, offering relief to patients unresponsive to traditional therapies. The favorable reimbursement policies, rising aging population, increasing healthcare expenditure, and increased awareness of inflammation's are the most prominent factors that are propelling the market demand across the globe.
In addition, the surge in autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, and ulcerative colitis is a pivotal driver propelling market expansion. For instance, a study released by the NCBI in August 2021 reported a 3% prevalence of psoriasis among adults aged 20 years or older in the U.S., underlining the momentum in this arena. Likewise, according to the NCBI article published in September 2022, the incidence of rheumatoid arthritis in Northern Europe and Northern America was 24 and 36 cases per 100,000 people, respectively. Moreover, the swift adoption of biologics for treating inflammatory diseases and the favorable reimbursement landscape for biological therapies are poised to further bolster market advancement. Furthermore, the rise in investment in research activities for the development of biologics, as well as the growing advancements is biotechnology presents various lucrative opportunities over the forecasting years. However, the side effects of anti-inflammatory drugs and the lack of inclination for biologics as first line of treatment are hindering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Anti-Inflammatory Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the surge in demand for anti-TNF drugs and promising pipeline candidates, serving as primary drivers propelling market growth. Furthermore, the strategic positioning of key players and robust sales of their pharmaceuticals in the region are anticipated to further bolster market expansion in North America. Whereas, Asia Pacific region is expected to grow the fastest over the forecast years. The increasing prevalence of diverse inflammatory disorders, rising healthcare spendings, and growing awareness regarding the available treatment options for these conditions are significantly propelling the market demand across the region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of tables and figures and dummy in nature, final lists may vary in the final deliverable